EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Inverse Agonists of Peroxisome Proliferator-Activated Receptor Gamma: Advances and Prospects in Cancer Treatment

Wensong Deng, Xuejian Wang, Xinyu Niu, Xiangjie Zhang, Yunlei Hou iD, Mingze Qin iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c00673 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Wensong Deng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Drug Inverse Agonism, Neoplasms, PPAR gamma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 125 Literaturangaben. Gefördert von: Shenyang Pharmaceutical University, Liaoning Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-dependent nuclear transcription factor that modulates metabolic homeostasis and cell proliferation. Inverse agonism of PPARγ is an emerging anticancer strategy, particularly for the treatment of bladder cancer. The first-in-class PPARγ inverse agonist, FX-909, is currently being studied in clinical trials for cancer treatment. However, PPARγ inverse agonists are still in the early stages of development. The discovery of compounds with novel chemical structures, potent efficacy, and favorable pharmacokinetic properties is urgently needed. In this perspective, the biological functions of PPARγ and its role in cancer pathology are introduced, and currently available PPARγ inverse agonists and their preliminary structure-activity relationships (SARs) are discussed from a medicinal chemistry viewpoint. These findings inform the development of anticancer agents that act as PPARγ inverse agonists. Furthermore, our discussion of the complex biological functions of PPARγ provides insights into the exploration of its role in various diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsDrug Inverse AgonismNeoplasmsPPAR gammaNitrilesQuinolinesAnimalsHumansStructure-Activity Relationship

Substanzen

Antineoplastic AgentsPPAR gammaNitrilesQuinolinesFX-909

Autor:innen und Institutionen

  • Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China.

ORCID-Profile: Yunlei Hou, Mingze Qin

Förderung

  • Shenyang Pharmaceutical University
  • Liaoning Province

Zitieren

APA

Deng, W., Wang, X., Niu, X., Zhang, X., Hou, Y., & Qin, M. (2025). Inverse Agonists of Peroxisome Proliferator-Activated Receptor Gamma: Advances and Prospects in Cancer Treatment. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00673

Vancouver

Deng W, Wang X, Niu X, Zhang X, Hou Y, Qin M. Inverse Agonists of Peroxisome Proliferator-Activated Receptor Gamma: Advances and Prospects in Cancer Treatment. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c00673

BibTeX
@article{Deng2025,
  author = {Deng, Wensong and Wang, Xuejian and Niu, Xinyu and Zhang, Xiangjie and Hou, Yunlei and Qin, Mingze},
  title = {Inverse Agonists of Peroxisome Proliferator-Activated Receptor Gamma: Advances and Prospects in Cancer Treatment},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c00673}
}
Kostenlos starten →